Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab-Reference-Cited by-同舟云学术

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab

Published:2021-06-15 Issue:9 Volume:42 Page:3523-3526
ISSN:1590-1874
Container-title:Neurological Sciences
language:en
Short-container-title:Neurol Sci

Author:

Gallo Antonio^ORCID,Capuano Rocco,Donnarumma Giovanna,Bisecco Alvino,Grimaldi Elena,Conte Miriana,d’Ambrosio Alessandro,Coppola Nicola,Galdiero Massimiliano,Tedeschi Gioacchino

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Neurology (clinical),Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10072-021-05397-7.pdf

Reference10 articles.

1. Salter A, Fox RJ, Newsome SD et al (2021) Outcomes and Risk factors associated with SARS-CoV-2 infection in a North American Registry of patients with multiple sclerosis. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2021.0688

2. Sormani MP, De Rossi N, Schiavetti I et al (2021) Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. https://doi.org/10.1002/ana.26028

3. Bar-Or A, Calkwood JC, Chognot C et al (2020) Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology 95:e1999–e2008. https://doi.org/10.1212/WNL.0000000000010380

4. Kappos L, Mehling M, Arroyo R et al (2015) Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology 84:872–879. https://doi.org/10.1212/WNL.0000000000001302

5. Jeyanathan M, Afkhami S, Smaill F et al (2020) Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol 20:615–632

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SARS-CoV-2 Vaccination Responses in Anti-CD20-Treated Progressive Multiple Sclerosis Patients Show Immunosenescence in Antigen-Specific B and T Cells;Vaccines;2024-08-17

2. Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients;Nature Communications;2024-03-29

3. COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients;Journal of Neurology;2023-11-20

4. Metabolic pathways engaged by antigen-specific T and B cells after SARS-CoV-2 vaccination in multiple sclerosis patients on different immunomodulatory drugs reveal immunosenescence and predict vaccine efficacy.;2023-11-17

5. Longevity of the humoral and cellular responses after SARS-CoV-2 booster vaccinations in immunocompromised patients;European Journal of Clinical Microbiology & Infectious Diseases;2023-11-13